Literature DB >> 31498995

The Effect of Antibody Fragments on CD25 Targeted Regulatory T Cell Near-Infrared Photoimmunotherapy.

Ryuhei Okada1, Yasuhiro Maruoka1, Aki Furusawa1, Fuyuki Inagaki1, Tadanobu Nagaya1, Daiki Fujimura1, Peter L Choyke1, Hisataka Kobayashi1.   

Abstract

Regulatory T (Treg) cells play a major role in immune suppression permitting tumors to evade immune surveillance. Depletion of intratumoral Treg cells can result in tumor regression. However, systemic depletion of Tregs may also induce autoimmune adverse events. Near-infrared photoimmunotherapy (NIR-PIT) is a newly developed cell-specific cancer therapy that locally kills specific cells in the tumor. Antibody-photoabsorber (IRDye700DX) conjugates (APC) are injected and bind to the tumor, and subsequent administration of NIR light to the tumor results in rapid cell death only in targeted cells. CD25-targeted NIR-PIT has been shown to induce spatially selective depletion of tumor-associated Treg cells. In this study, we compared the efficacy of an antibody fragment, anti-CD25-F(ab')2, and a full antibody, anti-CD25-IgG, as agents for NIR-PIT. Tumor-bearing mice were divided into four groups: (1) no treatment; (2) anti-CD25-IgG-IR700 i.v. only; (3) anti-CD25-F(ab')2-IR700 i.v. with NIR light exposure; and (4) anti-CD25-IgG-IR700 i.v. with NIR light exposure. Although both CD25-targeted NIR-PITs resulted in significant tumor growth inhibition, the anti-CD25-F(ab')2-IR700 based NIR-PIT was superior to the anti-CD25-IgG-IR700 NIR-PIT. The anti-CD25-F(ab')2-IR700 demonstrated faster clearance from the body than the anti-CD25-IgG-IR700. Sustained circulation of anti-CD25-IgG-IR700 may block IL-2 binding on the activated effector T-cells decreasing immune response. In conclusion, anti-CD25-F(ab')2 based NIR-PIT was more effective in reducing tumor growth than anti-CD25-IgG based NIR-PIT. Absence of the Fc portion of the APC leads to faster clearance and therefore promotes a superior activated T cell response in tumors.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31498995      PMCID: PMC7413076          DOI: 10.1021/acs.bioconjchem.9b00547

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  35 in total

1.  Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

Authors:  S Onizuka; I Tawara; J Shimizu; S Sakaguchi; T Fujita; E Nakayama
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

2.  Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy.

Authors:  Kazuhide Sato; Noriko Sato; Biying Xu; Yuko Nakamura; Tadanobu Nagaya; Peter L Choyke; Yoshinori Hasegawa; Hisataka Kobayashi
Journal:  Sci Transl Med       Date:  2016-08-17       Impact factor: 17.956

Review 3.  Regulatory T cells in cancer immunotherapy.

Authors:  Atsushi Tanaka; Shimon Sakaguchi
Journal:  Cell Res       Date:  2016-12-20       Impact factor: 25.617

4.  Photoimmunotherapy targeting prostate-specific membrane antigen: are antibody fragments as effective as antibodies?

Authors:  Rira Watanabe; Hirofumi Hanaoka; Kazuhide Sato; Tadanobu Nagaya; Toshiko Harada; Makoto Mitsunaga; Insook Kim; Chang H Paik; Anna M Wu; Peter L Choyke; Hisataka Kobayashi
Journal:  J Nucl Med       Date:  2014-12-11       Impact factor: 10.057

5.  Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.

Authors:  F Vincenti; R Kirkman; S Light; G Bumgardner; M Pescovitz; P Halloran; J Neylan; A Wilkinson; H Ekberg; R Gaston; L Backman; J Burdick
Journal:  N Engl J Med       Date:  1998-01-15       Impact factor: 91.245

Review 6.  Overview of interleukin-2 function, production and clinical applications.

Authors:  Sarah L Gaffen; Kathleen D Liu
Journal:  Cytokine       Date:  2004-11-07       Impact factor: 3.861

7.  Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice.

Authors:  Emma Jones; Michaela Dahm-Vicker; Anna Katharina Simon; Angharad Green; Fiona Powrie; Vincenzo Cerundolo; Awen Gallimore
Journal:  Cancer Immun       Date:  2002-02-22

8.  Improved radioimaging and tumor localization with monoclonal F(ab')2.

Authors:  R L Wahl; C W Parker; G W Philpott
Journal:  J Nucl Med       Date:  1983-04       Impact factor: 10.057

9.  Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity.

Authors:  Mikako Ogawa; Yusuke Tomita; Yuko Nakamura; Min-Jung Lee; Sunmin Lee; Saori Tomita; Tadanobu Nagaya; Kazuhide Sato; Toyohiko Yamauchi; Hidenao Iwai; Abhishek Kumar; Timothy Haystead; Hari Shroff; Peter L Choyke; Jane B Trepel; Hisataka Kobayashi
Journal:  Oncotarget       Date:  2017-02-07

10.  Photoinduced Ligand Release from a Silicon Phthalocyanine Dye Conjugated with Monoclonal Antibodies: A Mechanism of Cancer Cell Cytotoxicity after Near-Infrared Photoimmunotherapy.

Authors:  Kazuhide Sato; Kanta Ando; Shuhei Okuyama; Shiho Moriguchi; Tairo Ogura; Shinichiro Totoki; Hirofumi Hanaoka; Tadanobu Nagaya; Ryohei Kokawa; Hideo Takakura; Masayuki Nishimura; Yoshinori Hasegawa; Peter L Choyke; Mikako Ogawa; Hisataka Kobayashi
Journal:  ACS Cent Sci       Date:  2018-11-06       Impact factor: 14.553

View more
  10 in total

1.  Quantitative Assessment of the Efficacy of Near-Infrared Photoimmunotherapy with Bioluminescence Imaging.

Authors:  Ryuhei Okada; Aki Furusawa; Peter L Choyke; Hisataka Kobayashi
Journal:  Methods Mol Biol       Date:  2022

Review 2.  Endoscopic Applications of Near-Infrared Photoimmunotherapy (NIR-PIT) in Cancers of the Digestive and Respiratory Tracts.

Authors:  Hideyuki Furumoto; Takuya Kato; Hiroaki Wakiyama; Aki Furusawa; Peter L Choyke; Hisataka Kobayashi
Journal:  Biomedicines       Date:  2022-04-04

3.  Selection of antibody and light exposure regimens alters therapeutic effects of EGFR-targeted near-infrared photoimmunotherapy.

Authors:  Ryuhei Okada; Takuya Kato; Aki Furusawa; Fuyuki Inagaki; Hiroaki Wakiyama; Daiki Fujimura; Shuhei Okuyama; Hideyuki Furumoto; Hiroshi Fukushima; Peter L Choyke; Hisataka Kobayashi
Journal:  Cancer Immunol Immunother       Date:  2022-01-11       Impact factor: 6.630

4.  Opening up new VISTAs: V-domain immunoglobulin suppressor of T cell activation (VISTA) targeted near-infrared photoimmunotherapy (NIR-PIT) for enhancing host immunity against cancers.

Authors:  Hiroaki Wakiyama; Aki Furusawa; Ryuhei Okada; Fuyuki Inagaki; Takuya Kato; Hideyuki Furumoto; Hiroshi Fukushima; Shuhei Okuyama; Peter L Choyke; Hisataka Kobayashi
Journal:  Cancer Immunol Immunother       Date:  2022-04-21       Impact factor: 6.630

5.  Local Depletion of Immune Checkpoint Ligand CTLA4 Expressing Cells in Tumor Beds Enhances Antitumor Host Immunity.

Authors:  Ryuhei Okada; Takuya Kato; Aki Furusawa; Fuyuki Inagaki; Hiroaki Wakiyama; Peter L Choyke; Hisataka Kobayashi
Journal:  Adv Ther (Weinh)       Date:  2021-02-24

Review 6.  Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology.

Authors:  Ernesto Bockamp; Sebastian Rosigkeit; Dominik Siegl; Detlef Schuppan
Journal:  Cells       Date:  2020-09-15       Impact factor: 6.600

Review 7.  Near-Infrared Photoimmunotherapy (NIR-PIT) in Urologic Cancers.

Authors:  Hiroshi Fukushima; Baris Turkbey; Peter A Pinto; Aki Furusawa; Peter L Choyke; Hisataka Kobayashi
Journal:  Cancers (Basel)       Date:  2022-06-17       Impact factor: 6.575

8.  Highly versatile cancer photoimmunotherapy using photosensitizer-conjugated avidin and biotin-conjugated targeting antibodies.

Authors:  Naoto Shirasu; Hirotomo Shibaguchi; Hiromi Yamada; Masahide Kuroki; Shin'ichiro Yasunaga
Journal:  Cancer Cell Int       Date:  2019-11-15       Impact factor: 5.722

9.  Interleukin-15 after Near-Infrared Photoimmunotherapy (NIR-PIT) Enhances T Cell Response against Syngeneic Mouse Tumors.

Authors:  Yasuhiro Maruoka; Aki Furusawa; Ryuhei Okada; Fuyuki Inagaki; Hiroaki Wakiyama; Takuya Kato; Tadanobu Nagaya; Peter L Choyke; Hisataka Kobayashi
Journal:  Cancers (Basel)       Date:  2020-09-10       Impact factor: 6.639

10.  Immunomodulatory activity of IR700-labelled affibody targeting HER2.

Authors:  Justyna Mączyńska; Chiara Da Pieve; Thomas A Burley; Florian Raes; Anant Shah; Jolanta Saczko; Kevin J Harrington; Gabriela Kramer-Marek
Journal:  Cell Death Dis       Date:  2020-10-20       Impact factor: 8.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.